# BioMarin Pharmaceutical Inc.  Share Price Target ‘$106.78’, now 30.0% Upside Potential

- Link: https://www.directorstalkinterviews.com/biomarin-pharmaceutical-inc.share-price-target-106.78-now-30.0-upside-potential/4121154367
- Published: 2024-05-01T13:45:58+01:00
- Author: Charlotte Edwards

**BioMarin Pharmaceutical Inc.** with ticker code (BMRN) now have 25 confirmed analysts
covering the stock with the consensus suggesting a rating of ‘buy’. The range between
the high target price and low target price is between $140.00 and $46.00 suggesting
an average analyst share price target price of $106.78. (at the time of writing).
Now with the previous closing price of $82.13 this would imply there is now a potential
upside of 30.0%. The 50 day moving average now sits at $87.32 while the 200 day 
moving average is $89.02. The company has a market capitalization of 15.33B. The
stock price for the company is currently is currently $80.76 USD

 The potential market cap would be $19,937,175,861 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 76.19, revenue per share of $13.12
and a 1.77% return on assets.

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops
and commercializes therapies that address the root cause of genetic conditions. 
The Company’s portfolio consists of seven commercial products and multiple clinical
and preclinical product candidates for the treatment of various diseases. BioMarin’s
commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), 
Kuvan (sapropterin dihydrochloride), Palynziq (pegvaliase-pqpz), Brineura (cerliponase
alfa), Roctavian (valoctocogene roxaparvovec) and Voxzogo (vosoritide). The Roctavian
is an adeno associated virus (AAV5) vector drug development candidate designed to
restore factor VIII plasma concentrations in patients with severe hemophilia A. 
The Company’s clinical development programs include BMN 331, an AAV5 mediated gene
therapy for people living with Hereditary Angioedema (HAE) and BMN 255 is a small-
molecule therapy that is designed to treat hyperoxaluria in chronic liver disease.

Share on: